Cara Therapeutics Культура компании

Dr. Mani Mohindru, Ph.D. has been Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics, Inc. since August 15, 2017. Dr. Mohindru served as the Chief Strategy Officer of Curis, Inc. since March 29, 2016 until August 14, 2017 and its Senior Vice President until August 14, 2017. Dr. Mohindru serves as an Analyst at ThinkEquity LLC, Research Division. She also co-founded Immtox LLC. Dr. Mohindru served as Senior Vice President of Corporate Strategy & Investor Relations at Curis, Inc. since April 2015. Dr. Mohindru served as Vice President of Corporate Strategy and Investor Relations at Curis, Inc. from June 2013 to March 2015. She served as Managing Director in healthcare investment banking at Capstone Investments. She served as Associate Analyst of UBS Investment Bank, Research Division. Dr. Mohindru served as Equity Analyst of Cr???dit Suisse First Boston, Inc., Research Division. She served as Research Analyst at Cr???dit Suisse AG, Research Division. She spent several years as a Wall Street equity research analyst covering the biotechnology sector, including analyst roles at ThinkEquity LLC, Credit Suisse Securities and UBS Securities. She was a Healthcare Industry Consultant at Axon Healthcare Partners. She worked with major biopharmaceuticals companies advising them on various strategic initiatives during her tenure as a Healthcare Consultant at a firm that is part of IMS Health. Dr. Mohindru received a PhD in Neurosciences from Northwestern University in Neurosciences. She also holds a Master's degree in Biotechnology and a Bachelor of Sciences degree in Human Biology with honors in Human Physiology, both from the All Indian Institute of Medical Sciences, India.

Dr. Michael E. Lewis, Ph.D., co-founded Cara Therapeutics, Inc. and has been its Chief Scientific Advisor since September 2004. Dr. Lewis served as Secretary at Cara Therapeutics Inc. Dr. LewisDr. Lewis has been the President of BioDiligence Partners, Inc. since 1994. Dr. Lewis has more than 30 years of scientific experience in academic, government laboratories, several major pharmaceutical and also in bio-technology companies. He co-founded Arena Pharmaceuticals, Inc. in 1997 and served as its Chief Scientific Advisor from 1997 to 2003. He also co-founded Adolor Corporation in 1994 and served as its Chief Scientific Advisor from 1994 to 1997 and also participated on their analgesics development team and assisted in pre-IPO financing and corporate partnering presentations. Dr. Lewis served as a Vice President of Research for Symphony Pharmaceuticals from 1993 to 1994. He co-founded Cephalon, Inc., where he served as Senior Scientist, Director of Pharmacology and Senior Director of Scientific Affairs, from 1988 to 1993. Prior to that, he supervised as a Principal Investigator of E. I. DuPont de Nemours & Co., Inc. from 1985 to 1987. Prior to that, about five years of experience in opioid research at the National Institutes of Health and the University of Michigan. He served as a Director at Cara Therapeutics, Inc. since September 2004 until July 2010. He served as an Independent Director of PolyMedix, Inc., since November 2005 until March 29, 2013. Dr. Lewis served as a Director of Aeolus Pharmaceuticals Inc. (formerly Incara Pharmaceuticals Corp.) from June 2004 to May 2013. He served as a Director of PolyMedix Pharmaceuticals Inc. He served as a Pre-IPO Director of Arena Pharmaceuticals Inc. from 1997 to 2000. He is an inventor or co-inventor on 15 issued U.S. patents and is an author or co-author of over 40 publications on opioids, including journal articles, invited reviews and book chapters. Dr. Lewis participated in pre- and post-IPO road shows in Japan and the U.S and presentations to obtain corporate partners, including Schering-Plough and Kyowa Hakko. Dr. Lewis received a B.A. with Special Honors in Psychology from the George Washington University and an M.A. and Ph.D. in Psychology from Clark University in 1977, followed by postdoctoral training in Neurosciences at the University of Cambridge, postdoctoral training in Pharmacology at the National Institutes of Health and the University of Michigan.

Mani Mohindru serves as the CFO and Chief Stratgey Officer of Cara Therapeutics. Mani started at Cara Therapeutics in August of 2017. Mani is currently based in the Greater New York City Area.

Jo Goncalves serves as the Chief Medical Officer of Cara Therapeutics. Jo started at Cara Therapeutics in October of 2018. Jo is currently based in the Greater New York City Area.

Eric Vandal serves as the Vice President, Commercial Operations of Cara Therapeutics. Eric started at Cara Therapeutics in June of 2014. Eric is currently based in the Greater New York City Area.

Scott Terrillion serves as the General Counsel, Secretary and Chief Compliance Officer of Cara Therapeutics. Scott started at Cara Therapeutics in November of 2016. Scott is currently based in the Greater New York City Area.